May 18th 2024
Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
US Payer Perspectives on Evidence for Formulary Decision Making
May 10th 2012To improve formulary design processes and support payers in providing more effective healthcare, policy makers should consider involving commercial payers in the development of comparative effectiveness research and creation of research and treatment guidelines.
Read More
Classification of Health Plans Based on Relative Resource Use and Quality of Care
This study examines variation among health plans in resource use and quality of care for patients with diabetes mellitus or cardiovascular disease.
Read More
The Structure of Risk Adjustment for Private Plans in Medicare
Health plan accounting data are used to test how well the CMSHCC risk adjustment system tracks relative costs of treating various diagnoses: not very well.
Read More
Identification of Patients Likely to Benefit From Care Management Programs
Three approaches to prospective patient identification for care management programs were compared: predictive modeling, selection by primary care physician, and a combination of both.
Read More
Do Economic Evaluations of Targeted Therapy Provide Support for Decision Makers?
May 17th 2011Economic evaluations of adjuvant trastuzumab were reviewed. Three primary shortcomings were identified including incorporation of local data and estimation and representation (visual) of decision uncertainty.
Read More
Health Plan Resource Use Bringing Us Closer to Value-Based Decisions
There is a critical need for comparative information about plan resource use to support value-based purchasing efforts.
Read More